内阁 发表于 2025-3-28 17:24:16
Vija Bergs Lusebrinkacute lesions on magnetic resonance imaging. Using the assessment guidelines of the American Academy of Neurology, the level of efficacy for onaA and abobotulinumtoxinA in this form of cLBP (with the aforementioned technique) is C (possibly effective) based on one class II study conducted with each国家明智 发表于 2025-3-28 22:20:36
Vija Bergs Lusebrinkolled studies. One study demonstrated efficacy for onaA using a validated pain scale (level B, probably effective) and another for aboA using a scale of 0–5 for assessment of pain. In cerebral palsy (CP), one blinded study reported significant relief of spasticity-related pain after administration oOVERT 发表于 2025-3-29 02:35:51
Vija Bergs Lusebrinktulinum toxin A is a relatively novel treatment for PF. The results of two double-blind, placebo-controlled studies have supported its efficacy (level B). A comparator-blinded study has shown that BoNT-A is more effective than betamethasone in relieving pain and improving function at 6 months. Furthfalsehood 发表于 2025-3-29 04:06:12
http://reply.papertrans.cn/47/4616/461573/461573_44.pngForsake 发表于 2025-3-29 10:39:35
http://reply.papertrans.cn/47/4616/461573/461573_45.png把手 发表于 2025-3-29 14:55:51
http://reply.papertrans.cn/47/4616/461573/461573_46.pngFoam-Cells 发表于 2025-3-29 16:18:09
http://reply.papertrans.cn/47/4616/461573/461573_47.png